AAM Blasts Build Back Better But Bernstein Offers Balance
Discounted Drugs Could Disincentivize US Biosimilar Competition, Says AAM
Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.
You may also be interested in...
Craig Burton is stepping up to become executive director of the US Association for Accessible Medicines’ Biosimilars Council, as Christine Simmon has moved on to become president and CEO of the Food and Drug Law Institute. At the same time, Burton has added oversight of strategic alliances to his existing policy role with the AAM.
Joe Manchin’s refusal to vote in favor of the Biden administration’s Build Back Better legislation could prove to be a boon for the US biosimilars industry, following weeks of condemnation from the Association for Accessible Medicines.
The Build Back Better Act has been updated to exempt generics experiencing or at risk of shortage from its planned inflation rebates, as well as biosimilars. But the US Association for Accessible Medicines has called for further changes to the proposed bill to protect off-patent drugs.